SLDX Stock STELLA DIAGNOSTICS (SLDX, $0.04) 50-day Moving Average exceeded its 200-day Moving Average on July 31, 2025
at Tickeron.com
SLDX's Stochastic Oscillator remains in oversold zone for 19 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Momentum Indicator moved above the 0 level on August 29, 2025. You may want to consider a long position or call options on SLDX as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SLDX just turned positive on August 29, 2025. Looking at past instances where SLDX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
SLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for SLDX moved below the 200-day moving average on July 31, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for SLDX entered a downward trend on September 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (10.423). P/E Ratio (0.000) is within average values for comparable stocks, (140.836). SLDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.686). Dividend Yield (0.000) settles around the average of (0.022) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.722).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SLDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Advertisement
General Information
Industry MedicalSpecialties